Trafficking and retention of protein antigens across systems and immune cell types

Thu A. Doan1,2 · Tadg Forward1 · Beth A. Jirón Tamburini1,2,3

Received: 13 December 2021 / Revised: 1 April 2022 / Accepted: 12 April 2022 / Published online: 3 May 2022
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Abstract
In response to infection or vaccination, the immune system initially responds non-specifically to the foreign insult (innate) and then develops a specific response to the foreign antigen (adaptive). The programming of the immune response is shaped by the dispersal and delivery of antigens. The antigen size, innate immune activation and location of the insult all determine how antigens are handled. In this review we outline which specific cell types are required for antigen trafficking, which processes require active compared to passive transport, the ability of specific cell types to retain antigens and the viruses (human immunodeficiency virus, influenza and Sendai virus, vesicular stomatitis virus, vaccinia virus) and pattern recognition receptor activation that can initiate antigen retention. Both where the protein antigen is localized and how long it remains are critically important in shaping protective immune responses. Therefore, understanding antigen trafficking and retention is necessary to understand the type and magnitude of the immune response and essential for the development of novel vaccine and therapeutic targets.

Keywords Lymph node · Spleen · Mucosa · Immunology · Antigen processing · Vaccination · Infection · Antigen archiving · Antigen retention · Antigen persistence · Antigen trafficking · Lymphatic endothelial cell · Dendritic cell

Introduction
Protein antigen trafficking involves the transport of self or foreign proteins (antigens) through the tissue via lymphatics to the lymph node (LN) or through the blood to the spleen, where immune surveillance occurs. Antigen trafficking usually occurs within 1–3 days (Fig. 1a). While there are other types of antigens (e.g., lipids, polysaccharides, nucleic acids) this review will focus primarily on protein antigens. Current understanding of protein antigen trafficking has relied largely on the fluorescent conjugation of soluble protein antigens [1–5], labeled nanoparticles [6] or infrared dye (IR) conjugation of virus-like particles (VLP) [7] in mice. Antigen location can be determined by immunofluorescence using highly sensitive detection methods or genetically engineering expression of fluorophores within the viral or bacterial genome, e.g., vaccinia virus labeled with mCherry or GFP [4, 8–11]. These tools have facilitated a greater understanding of how antigens are handled in different locations throughout the body and the cell types involved.

Protein transport through organ systems
In this section, we will discuss what is known about where protein antigens traffic upon entering the body, how protein antigens get to the LN and spleen, the mucosa, and new insights into how proteins traffic through the brain. We will also discuss tissue specific cell types involved in acquiring or trafficking protein antigens to shape the immune response.

Antigen trafficking within the LN and spleen
The function of the LN is to survey antigens, pathogens and debris from lymphatic fluid that drains from the other tissues of the body (e.g., skin, liver, gut, lung, brain, etc.). The
Lymph node

- migratory cDC1s and cDC2s traffic antigens from other tissues (epidermis, gut, etc.) to the LN. LN-resident cDC1s and cDC2s capture and present antigens within the LN.
- Lymph node sinus DCs extend dendrites into sinuses to capture lymph-borne antigens.
- CD103+ epithelial DCs can extend their processes to sample lymphatic fluids or capture large antigens.
- Ly6C+ MHCII+ monocytes traffic soluble antigens.
- CD44+ lymph node sinus DCs present antigens to follicular B cells.

Spleen

- CD16+ macrophages present antigens to marginal zone B cells.
- Lymph node antigen-presenting DCs present antigens to follicular B cells.
- N-terminus of CD16+ macrophages can extend their processes to sample the blood or capture large antigens.

**Legend**

- T cell
- CD11c+ macrophage
- marginal zone macrophage
- LN-resident CD103+ DC
- lymph node sinus DC
- Ly6C+ MHCII+ monocytes
- follicular B cells
- marginal zone B cells
- fibroblast
- neutrophil
- bacteria
- viruses
- soluble antigens
Fig. 1 Trafficking of antigens to the lymph node and spleen. a Timing of antigen trafficking is approximately 1–3 days. b Migratory DCs, both cDC1 and cDC2, traffic different antigens from the periphery to the draining LN via the lymphatics. LN-resident cDCs can capture antigens that are passively transported through the lymphatics to the LN and present the antigens to naïve T cells [3, 62–64]. c Lymphatic sinus DC (cDC2) extend dendrites into the subcapsular sinus to acquire lymph-borne antigens [73]. d In the spleen, cDC1s can traffic bacteria, such as Listeria monocytogenes, from the red pulp to the white pulp [76]. e Langerhan cells (located in the epithelium and dermal dendritic cells (DDC) (located in the dermis) traffic different antigens from the skin to draining LN via the lymphatics [82]. XCR1 + DDC (cDC1s) can acquire and traffic viral antigens, such as Herpes simplex virus 1 and vaccinia virus [19, 96–99]. f CD169+ metallophilic macrophages (also known as subcapsular sinus macrophages) capture incoming small antigens by extending their processes to sample the lymphatic fluids [11, 114, 115]. They can also capture larger, viral antigens, such as vesicular stomatitis virus [116]. g In the spleen, CD169+ metallophilic macrophage can sample the blood and capture large antigen in a similar manner as in the LN [11, 114–116]. h Ly6C+ MHCI + monocytes can acquire soluble antigens, such as ovalbumin, and migrate to the LN [124]. i In the spleen, CD169+ metallophilic macrophages capture blood-borne pathogens and hold the antigens within non-degradative endosomal compartments. These macrophages exchange intact antigens to marginal zone (MZ) B cells [129, 130]. j Small, soluble antigens diffuse from the conduit pores and traffic to the B cells follicles or other parts of the LN cortex [17, 132]. k CD169+ metallophilic macrophages sequester antigens near the sub-capsular sinus to exchange unprocessed antigen to follicular B cells [11, 134]. l DCs concentrated near the high endothelial venule (HEV) mediates presentation of unprocessed antigens to migratory B cells [135]. m Neutrophils can transport bacteria (Staphylococcus aureus) and fluorescent ova from the site of infection to the lymph nodes via theafferent lymphatics [140–142].

Organization and structure of the lymphatic vasculature in the tissues and the LN selectively allow entry to different locations within the LN based on antigen size [6]. The LN is surrounded by the lymphatic sinus which allows for entry of lymph through the afferent lymphatics and is home to large numbers of lymphocytes, macrophages, and antigen-presenting cells like dendritic cells (DCs) (Fig. 1). Most protein antigens that are encountered in the tissue (e.g., skin, lung, gut, brain) traffic via the lymph to the draining LN. The LN is arranged with B cell follicles on the outer edge near the lymphatic sinus [12]. The corticallymphatics reside in the space between the B cell follicles and branch into the cortex near the T cell zone [12]. The structural support of the LN is provided by several different types of fibroblasts that lymphocytes crawl along [13, 14]. The conduit system within the LN, comprised of fibroblastic reticular cells, begins at small holes in the subcapsular sinus and acts as a sieve where antigens and particulates smaller than 70kD or 4 nm can passively enter the system and the cortex of the LN (Fig. 1) [15–17]. Soluble protein antigens administered via immunization (30–50 kD) and viruses (20–100 nm) are small enough to passively flow through the lymphatics directly to the LN conduit system, while most bacteria (400–2000 nm) are too large to pass through the lymphatic capillaries in the LN and require active transport via migratory cells [6, 18, 19]. The ensuing immune response is largely affected by which type of antigen-presenting cells have access to the antigen. In the case of small antigens, both LN resident (passive transport) and migratory DCs (active transport) can acquire and present antigens (see DC subtypes in DC section). Follicular B cells, located in the B cell follicles, can also acquire small, soluble antigens that passively diffuse through the subcapsular sinus of the LN. Follicular B cells also encounter larger antigens which are actively transported by DCs and subcapsular sinus macrophages (discussed further in the B cells section).

High endothelial venules (HEV) are vascular structures within the lymph node important for the transport of lymphocytes from the blood. This function and maturation of the HEVs is highly regulated by CD11c+ DCs [20]. During fever, the upregulation of ICAM-1 and CCL21 causes increased lymphocyte transport across HEVs [21]. Neutrophils [22] and plasmacytoid DCs (pDCs) [23] actively transit through HEVs during infection or inflammation. As neutrophils (97, 98) and pDCs (56) are capable of trafficking antigen to the LN it is possible for these cells to traffic protein antigens from the blood through the HEVs (see Neutrophil and Dendritic cells sections).

In contrast to the LN, the spleen acquires protein antigens and pathogens that arise in the blood. The spleen consists of the red pulp and the white pulp. The red pulp filters and surveys the blood for antigens, pathogens and dead or dying cells (particularly red blood cells). The white pulp largely acts like a LN within the spleen and is organized in a similar manner with specific B cell zones, T cell zones and a sinus (Fig. 1) [24]. Many different myeloid cell types reside in the red pulp, and can traffic to the white pulp in a similar manner as DCs, monocytes, neutrophils and T cells traffic from the tissue through the lymph and to the LN. As such, many of the cell types involved in trafficking of antigens are similar between the spleen and LN. Therefore, the immune system has two major immune cell “hubs” where antigens traffic to initiate an immune response. One, the LN, that surveys the lymph from the tissue and two, the spleen, that surveys the blood.

Antigen transport through the respiratory and gastrointestinal mucosa

While the major sites of immune cell priming are the LN and spleen, several other tissue sites have specialized systems for antigen detection and trafficking based on their location. Detection of antigens, particularly vaccine antigens, given orally or nasally, has identified unique mechanisms of antigen acquisition and transfer within intestinal or respiratory mucosa. Oral or nasal mucosal protein antigen vaccines
must be formulated to activate innate signaling pathways for antigen to bypass an environment that is permissive or tolerant to normal flora. Within the mucosa, protein antigens passively enter through the epithelium [25] or are captured by microfold (M) cells and then transported across the epithelium for uptake/transfer to epithelial DCs [26]. M cells express clusterin, Siglec-F, Annexin V, and UEA1 in mice [27–30], and so far human M cells are known to express clusterin [29]. M cells are a specialized epithelial cell type found within the epithelial barrier that allow antigen entry into the mucosal lymphoid follicles (Table 1). Antigens entering the airway mucosa are captured by nasopharynx-associated lymphoid tissue (NALT) M cells or respiratory M cells [31]. When proteins or pathogens enter through the epithelium they can encounter the lymphatic structures [32]. Within the small intestinal villi is the lacteal which is a specialized lymphatic capillary with highly permeable “button like” junctions whose main function is to take up chylomicrons for fat absorption as demonstrated in mice [33]. Antigens (vaccine or pathogen derived) can be actively captured by DCs reaching through the epithelium or passively transported through the epithelium [34, 35]. In either case, once through the epithelium, the antigens are carried by intestinal DCs [34] or respiratory DCs through the lymphatic vasculature. Both the lacteals and submucosal lymphatics at the Peyer’s patches drain into the mesenteric lymphatics [36]. Passive antigen transport through the mucosal lymphatics has not been directly measured, though active cellular transport is well described [34, 35, 37–39]. In either case the antigens, passively or actively, would be transported into the mesenteric LNs [36]. Within the respiratory tract the antigens, either actively or passively, enter the lymphatics that drain to the mediastinal LNs in mice.

Antigens that pass through the M cells at intestinal or lung mucosal sites are carried by DCs to the lymphoid tissue where T and B cells can be activated for robust production of mucosal IgA. Mucosal vaccination is attractive because the vaccine initiated immune response is at the site where mucosal infections occur, and obviates the need for intramuscular injection. Mucosal vaccines licensed for clinical use in humans and animals are live attenuated or inactivated [40]. These vaccines include nasal (FluMist-Influenza A/B) and oral (Rotarix-rotavirus) delivery routes. Preclinical studies have attempted to target vaccine antigens to M cells to improve the efficiency of the immune response within the mucosal tissues in mice [41]. For example, vaccine antigens conjugated to an agonist (TLR2, 4, 9) [42] or a specific receptor expressed by M cells, such as a (1,2) fucose-containing carbohydrate [43], a Co1 ligand or a CSaR ligand, could target antigens to M cells. Targeting of antigens to M cells would optimize DCs recruitment to the follicle-associated epithelium where the DCs would become activated and promote an adaptive immune response [44, 45]. Other options for enhancing the immunogenicity of mucosal vaccines are virus-like particles and bacterial strains that overexpress antigens on their surface (reviewed in detail elsewhere [46]).

**Protein transport through the brain to the LN**

The brain is a highly specialized organ where inflammatory responses must be minimized. New studies have determined that removal of proteins and protein aggregates requires a drainage system within the brain that is somewhat unique to other systems. The lymphatic system, primarily studied in rodents, acts to remove interstitial fluid and protein, protein aggregates and other solutes that mix with cerebral spinal fluid (CSF) in the paravascular space. This transport of solutes is acellular, but does require Aquaporin 4 water channels in the astrocytes that line the brain vasculature to passively direct fluid flow toward the perivascular space [47]. The interstitial fluid collects in the perivascular space and drains out of the brain toward the cervical lymphatic system in rodents and non-human primates [48]. While there is still some debate about how the glymphatic and traditional lymphatic system cooperate it is thought that dural sinuses and meningeal arteries are lined with lymphatics which drain from the lymphatic system to the cervical lymph nodes [49, 50]. Several recent and interesting studies evaluated lymphatic drainage in the brain using fluorescently tagged protein antigen or diffusible solutes (Evan’s Blue) in mice. Following injection into the brain parenchyma of mice, these proteins were found to passively drain through the meningeal lymphatics to the deep cervical LNs and later the superficial cervical LNs [49–51]. While vaccination with protein antigens in the brain is not an attractive route of immunization, this mechanism of antigen trafficking is critical for removal of proteins and pathogens from the brain. Other studies have demonstrated the importance of sleep in the removal of protein via the brain glymphatics and lymphatics in mice [52, 53]. Further studies have linked the removal of proteins and protein aggregates to improved outcomes including decreased neural degeneration and dementia in mice and humans [54]. While this field is still relatively new and exciting, understanding how proteins traffic from the brain and through the deep cervical LN for clearance will improve our understanding of brain function, protein trafficking and immune activity. These studies clearly demonstrate how understanding protein and antigen trafficking can reveal novel discoveries that may improve overall health and well-being.

**Cell types involved in protein antigen trafficking**

Antigen trafficking within the LN, spleen, tissue, mucosa, and brain can occur passively, but ultimately leads to encounters with different immune cell types. Below we
Table 1 Overview of cell types that traffic or retain antigens

| Cell Type | Location | Time | Function upon antigen encounter | Mouse Markers | Human Markers |
|-----------|----------|------|---------------------------------|---------------|---------------|
| LN-resident cDC1 | resident: LN-resident cDC1 located deep in the cortex migratory: dermal DC (skin), CD11b+ DC (lungs and gut) | traffic antigens for approximately 1-3 days | antigen trafficking, antigen processing, antigen presentation acquire antigens via phagocytosis, macrophagocytosis, receptor-mediated endocytosis (e.g. mannose receptor, DEC-20) [213] | CD45+, CD11c+, XCR1+, CD11b+, CD133+, CD68+, CLEC9a+ (DGGR), MHC II+ [56] | CD141+ (BOAC3), CLEC9a+ (DGGR) [56] |
| migratory cDC1 | | | | | dendritic DC: CD45+, CD11c+, DCIR+ XCR1+, CD11b+, Clec9a+ Langerin+/-, CD103+/+ [83, 84] | |
| LN-resident cDC2 | resident: lymph node sinus DC located near subcapsular sinus migratory: dermal DC (skin), CD11b+ (lungs and gut) | traffic antigens for approximately 1-3 days | antigen trafficking, antigen processing, antigen presentation acquire antigens via phagocytosis, macrophagocytosis, receptor-mediated endocytosis (e.g. dectin, DCIR2, DC-SIGN) [213] | CD45+, CD11c+, Esam+, CD301b+ (MqD2), MHC II+ [57], CD11b+, XCR1-dermal DC: CD45+, CD11c+, CD11b+, MHCII+, either CD11b+ and SIRPα or low levels of CD11b and C3XCR1 [83, 84] | CD11c+ (BOAC1), SIRPα [59] |
| migratory cDC2 | | | | | dendritic DC: CD11c+ (BOAC1), CD11c+ [91] |
| Langerhan cell | skin to LN | traffic antigens for approximately 1-3 days | antigen trafficking, antigen presentation, receptor-mediated endocytosis (e.g. Langerin, DEC-205) [213] | CD45+, CD11c+, CD11b+, Langerin+ (CD207), Epcam+, Siporin+ [83, 84] | CD11c+ Langerin+ (CD207), Birbeck granules+ [85] |
| CD169+| subcapsular sinus of LN or near marginal zone of spleen | hold antigens up to 3 days | antigen trafficking, antigen retention endocytose antigens via FoxyM [129] | CD45+, CD11b+, F4/80+, MHC II, MHC II+ [113, 117, 120] | CD169+ [117] |
| Ly6C+MHCII+ monocytes | site of infection to LN | traffic antigen for 1-4 days | antigen trafficking | CD45+, CD11b+, MHC II+, Ly6C+ [122-124] | CD14+, CD16+ [122] |
| marginal zone B cell | marginal zone of spleen | traffic antigens for approximately 1-3 days | antigen trafficking, endocytose antigens via BCR [133] | CD45+, B220+, CD11b+, CD21+ [126, 127] | CD10+ (BOCA1), CD19+ [126, 127] |
| | | | | high IgM, low IgD [127, 128] | high IgM, low IgD [127, 128] |
| follicular B cell | B cell follicles of LN and spleen | displayed peptide on MHC for approximately 24 hr | antigen trafficking internalize B cell receptor-bound antigens [133] | CD45+, B220+, CD11b+, MHC II+, CD23+ [126, 127] | CD10+, HLA-DR+ [126, 127] |
| | | | | low IgM, high IgD [127] | low IgM, high IgD [127] |
| neutrophil | site of infection to LN | traffic antigens to LN (unknown time) | antigen trafficking | CD45+, CD11b+, Ly6G+ [137-139] | CD45b+, CD11b+, MPD+, elastase+ [137-139] |
| microfold (M) cell | Peyer's patches | - | antigen exchange transport proteins (secretory IgA) via dectin-1 and Siglec-5 [214] | CD45+, Siglec-F+, clusterin+, Annexin V+, UEA1+ [27-30] | clusterin+ [29] |
| follicular dendritic cell (FDC) | B cell follicles of LN | retained antigens for several weeks-years | antigen persistence antigens held in antigen/antibody complexes [159, 157-161] | CD45+, CR1+ (CD35), CR2+ (CD21) [153, 157-161] | CR1+ (CD35), CR2+ (CD21), CR3+ [162, 163] |
| lymphatic endothelial cell (LEC) | sinuses of LN (subcapsular, cortical medulary LEcs) | archived antigens for 51 weeks | antigen archiving/persistence antigen exchange antigen uptake via clethrins/caveolin-mediated endocytosis [5] | CD45+, VEGFR3+, LVVE1+, Prox1+, podoplanin+ [5, 166-173] | CD45+, VEGFR3+, LVVE1+, Prox1+, podoplanin+ [5, 166-173] |
| Na4a1+ and CD34+ fibroblasts | conduit of LN | up to 2 weeks | antigen persistence | CD45, Na4a1 or CD34 [5] | unknown |

Yellow colored boxes indicate cells that traffic antigens. Purple colored boxes indicate cells that retain antigens. The location of each cell type and the timing of antigen trafficking or retention are shown. For the cell types that have known endocytosis receptors, we have listed them in the function column. For example, cDC1s use mannose receptor and DEC-205, cDC2s use dectin, DCIR2 and DC-SIGN [213], and M cells can transport proteins via dectin-1 and Siglec-5 [214]. Respective mouse and human markers for each cell type are also listed.
Dendritic cells

Dendritic cells (DCs) are professional antigen-presenting cells (APC) that are essential for the initiation and control of adaptive immune responses. DCs specialize in acquiring and processing antigens to present to naïve or memory T cells via major histocompatibility complex (MHC) molecules. DCs also express necessary co-stimulatory molecules that help in the activation of T cells. As sentinel APCs, DCs survey peripheral tissues, such as the skin, to acquire foreign antigens, migrate to the draining LN and present the antigens to T cells to initiate adaptive immune responses. There are several different classifications of DCs, both lymphoid and tissue specific, whose main functions are to acquire, traffic, process, and present antigens. These different classes are outlined below with a focus on their role in antigen acquisition, recognition and transport.

Within each of the tissues are cDC1 and cDC2, often classified based on the tissue type, while pDCs are typically only found in the secondary lymphoid organs and blood. The development of each DC subset is controlled by specific transcription factors. In both mice and humans, the cDC1 development and survival requires interferon regulatory factor 8 (IRF8) and basic leucine zipper ATF-like transcription factor 3 (BatF3) [55]. In mice, cDC1 are further defined by their expression of XCR1, CD103, and CD8α, while in humans, cDC1 are defined by their expression of CD141 (BDAC3) (Table 1) [56]. Expression of CLEC9a (DNGR1) on cDC1 is common between the two species. In contrast, cDC2s exhibit more heterogeneity than cDC1s. They have variable expression of Esam and CD301b (Mgl2) [57]. The cDC2s require IRF4 for their development in mice [58], while it is unclear if human cDC2 also requires IRF4. Human cDC2s expressed CD1c (BDAC1) and SIRPα (Table 1). Brown et al. [59] demonstrated in mice that cDC2s can be further classified based on the presence or absence of T-bet. They described T-bet⁺ cDC2A to have anti-inflammatory properties and express Runx3 and SREBF2 while T-bet⁻ cDC2B have pro-inflammatory properties and rather express the transcription factor RORγt and the cell surface molecules, CLEC12A and CLEC10A (Table 1). In humans, only the cDC2B subset was found in the blood [59], but the group suggested that the cDCA population may be found in human lymphoid tissues [59]. In mice and humans, pDCs require IRF7, IRF8 and TCF4 for their differentiation and maintenance [55, 60, 61].

Conventional DCs

Conventional dendritic cells (cDCs) can present both peptide and lipid antigens to T cells. cDC1s are important in cross-presentation, which is the process by which exogenous antigens are displayed on MHC class I to be presented to naïve CD8⁺ T cells (Fig. 1b). In the mouse, lymphoid-resident cDC1s express toll-like receptor (TLR) 3, 4, 9, 11, 12, 13, and STING, while migratory cDC1s express TLR1, 3, 6, 8, 11, 12, and STING [59]. In humans, lymphoid-resident cDC1s express TLR3, 8, 10, and STING. So far, it is only known that human migratory cDC1s express TLR3 [59]. In contrast, cDC2 generally uses the MHC class II pathway to present peptide antigens to CD4⁺ T cells but can also cross-present soluble vaccine antigens via MHC class I to CD8⁺ T cells under certain conditions in mice (Fig. 1b) [3, 62–64]. Based on analysis of differential gene expression, Brown et al. demonstrated that cDC2A subset express TLR1, 5, and 7 and cDC2B subset express TLR1, 2, 5, 6, 7, and 8 [59].

DCs can also present microbial lipid antigens via CD1 isoforms (CD1a, CD1b, CD1c). Interestingly, the presentation of lipid antigens via CD1b is not limited to the state of DC maturation. CD1b can present lipid and glycolipid antigens on immature DC and mature DC, while MHC class II is limited to presentation of peptide antigens only on mature DC [65, 66]. CD1b expressing DCs can present to αβ T cells [67, 68] and a recent study demonstrated that CD1b can be recognized by human γδ T cells [69].

Within each cDC subset there are both migratory and spleen/LN-resident populations. cDC migration from the tissue to dLNs requires transport via the lymphatic vasculature where the CCR7 expressing DCs are exposed to gradients of chemokines, specifically CCL19/21 [70–72]. For those antigens that are small enough to passively traffic through the lymphatics from the tissue and enter the subcapsular sinus, specific LN sinus (LS)-DCs (a subset of cDC2s) acquire the lymph-borne antigen (Fig. 1c) [73]. The LS-DCs are proximal to the LN lymphatic vasculature providing the LS-DCs with a unique opportunity to shape the immune response [73]. In contrast, LN-resident DCs (cDC1) located deep within the cortex of the LN present antigens to naïve CD8⁺ T cells. Thus, cDC1s located near CD8⁺ T cells often acquire cell-associated antigens and those antigens that require cross-presentation [1]. To aid in the active transport of antigens to the LN from the tissue are migratory DCs, which can localize to specific zones within the LN to prime T cells and appropriately shape the response. Splenic migratory DCs are also important for trafficking antigens acquired in the red pulp to the white pulp and require fibroblastic reticular cells [74, 75]. As an example, migratory cDC1s are thought to traffic Listeria monocytogenes from the red pulp to the white pulp in mice [76]. This process is thought to be co-opted by the bacteria to access the T cells within...
the white pulp [76] (Fig. 1d). Thus, cDCs express different pattern recognition receptors, present different types of antigens, and localize to specific regions within the tissue and lymphoid organs. Therefore, which cDCs encounter and traffic protein antigens for presentation can dramatically affect the adaptive immune response.

**Plasmacytoid DCs**

Plasmacytoid DCs (pDCs) are highly inflammatory and have been described to produce nearly one thousand times more type I interferon than cDCs [77]. Like cDCs, pDCs express MHC class II molecules and costimulatory molecules. These pDCs can present endogenous antigens via MHC class I and II molecules [78, 79]. Although pDCs can phagocytose soluble antigens, such as ovalbumin or hen egg lysozyme, it is still debatable whether pDCs present exogenous antigens as efficiently as cDCs do, particularly in the presence of cDCs [80, 81]. For example, ovalbumin taken up by pDCs, when inhaled, can be transported from the lungs into draining LNs in mice [80]. Thus, while pDCs are not a major contributor to DC antigen trafficking, they can traffic antigens either in the absence of cDC or under specific circumstances that require them to do so.

**Skin DCs**

In the skin, cDCs are found primarily in the dermal layer. Skin-derived DCs are important in trafficking antigens from the skin via afferent lymphatics to draining LNs (Fig. 1e) [82]. The DC subsets that reside within skin are Langerhans cells (LC) and dermal dendritic cells (DDCs) which have both unique and redundant functions. LCs share a common ontogeny with macrophages and are found within the epidermis, while DDCs are of the cDC ontogeny and are found within the dermis. Murine LCs are defined by CD11b, Epcam, Sirpα, and Langerin (CD207) [83, 84], while human LCs are characterized CD1a, Langerin (CD207), and Birbeck granules (Table 1) [85]. LCs can take up antigens and migrate to skin-draining LNs for presentation to naïve T cells with the peak of migration occurring after 72 h [86, 87]. LCs are structurally linked to E-cadherin-expressing keratinocytes [88]. To egress the epidermis, E-cadherin expression is decreased and further migration is aided by CXCR4 and EpCAM [89, 90]. Similar to migratory DDCs, activated LCs upregulate CCR7 and follow the CCL19/CCL21 chemokine gradient to the draining LNs. In addition to Langerhans cells, DDCs in the mouse express numerous markers based on their location and function and can be classified as cDC1 or cDC2. The cDC1 DDCs express XCR1, Clec9A, and Langerin (CD207) and can be further delineated based on CD103 expression (+ or −), while the cDC2 DDCs express either CD11b and Sirpα or low levels of CD11b and CX3CR1 (Table 1) [83, 84]. Human DDCs are divided into human CD1a+ DDCs and human CD14+ DDCs [91]. These two subsets also express CD1c (BD1c) and CD11c (Table 1). Following infection or intradermal vaccination, DDCs can phagocytose pathogenic material and antigens as well as upregulate CCR7 and MHC II to promote migration through the lymphatics and antigen presentation to naïve T cells within the draining LN [70, 92, 93]. The release of lipid mediators, cysteinyl leukotrienes, prostaglandin E_2 (PGE2) and expression of PD-L1 during inflammation aid in CCR7 recognition of CCL19/21, matrix metalloproteinase 9 (MMP9) expression and downstream signaling events [18, 94, 95]. When trafficking from the skin, dermal DCs are of critical importance. In bacterial skin infections, DDC migration to the LN is required for antigen presentation in the LN as most bacteria (400–2000 nm) are too large to pass through the lymphatic capillaries [6]. Further, XCR1+ dermal DCs, of the cDC1 lineage, were recently shown to be exceptionally important for cross-presentation of viral antigens from Herpes Simplex Virus-1 and Vaccinia Virus (VV) that infect skin cells, such as keratinocytes or dermal DCs [19, 96–99]. Thus, skin DCs are critically important for trafficking of antigens from the skin to the LN and mounting the appropriate immune response to each specific pathogen.

**Pulmonary DCs**

In the lungs, pulmonary cDCs traffic inhaled antigens to lung-draining LNs. Pathogen-derived or vaccine antigens are acquired by cDCs which then transport and present antigens in the lung-draining LNs. Within the lung tissue, migratory cDC1 have high expression of CD103 and low expression of CD11b (termed CD103+ DC). Conversely, migratory cDC2 express low levels of CD103 and high levels of CD11b (termed CD11b+ DC) [100]. Both cDC populations are represented at relatively similar frequency in the lungs. While CD103+ DCs are better at trafficking apoptotic cells, both are capable of trafficking viral antigens to draining LNs [101]. Trafficking of antigens by cDCs occurs as a result of chemokine receptor expression where decreased CCR6 expression and increased CCR7 promotes migration. The interaction of CCR7 with CCL19 and CCL21 ligands are similar in the lung and the skin [102]. Once the DCs arrive in the LN, CD103+ DC typically cross-present the antigenic peptide to CD8+ T cells while the CD11b+ DC presents the antigenic peptide to CD4+ T cells. Surprisingly, in the case of soluble antigens, both cDC1 and cDC2 subsets can present antigens via MHC class I or MHC class II [101]. Therefore, pulmonary DCs have specific functions within the lung that aid in tailoring T cell responses to protect the host from respiratory infection.
Intestinal DCs

DCs that occupy the gut mucosa are found within the mesentery, LNs [103], Peyer’s patches [104], the colon [103], and intestinal lamina propria [34]. Similar to other organs, DCs found within the gut tissue are comprised of cDC1 (CD103+CD11b−) and cDC2 (CD103−CD11b+). As foreign antigens pass through the intestinal epithelium they are captured within Peyer’s patches by microfold (M) cells. These M cells are uniquely suited to facilitate antigen transfer to mucosal DCs [25]. In addition to the transfer of antigens from M cells to cDCs, subepithelial dome resident DCs that express high levels of lysozyme extend dendrites across the M cell-specific transcellular pores to sample luminal antigens [105] in a similar manner as cDC2s at the lymphatic sinus (LS-DC) of the LN [73]. Small intestine goblet cells also can capture small antigens and IgA complexes for transport to DCs [106, 107]. In addition to the commonly described DC subsets, gut cDC2s can differentiate into CD103+CD11b+ DCs in the presence of TGFβ to promote Th17 and T regulatory CD4 T cell subset generation within the gut [108]. Upon encounter with antigens, the CD103+CD11b+ DC subset can induce Th17 development via the mannose receptor to cross-present AdLGO adenovirus-expressing ovalbumin which led to control of early viral infection [120] (Table 1). Furthermore, CD169+ macrophages in the LN can capture and present lipid antigens to iNKT cells, which is critical in the activation and rapid secretion of IL-4 and IFNγ by iNKT cells [118]. The expression of CD14 on the CD169+ macrophages allows iNKT to come into close proximity with these macrophages for antigen presentation.

Additional studies have illustrated how macrophages can both present antigens and exchange antigens with other cell types, such as DCs [119], to shape the immune response in the spleen. For example, like in the LN, splenic CD169+ macrophages can capture blood-borne pathogens and interact with CD8α+ DC to cross-prime CD8+ T cells (79). CD169 on the macrophages was critical for antigen transfer to the CD8α+ DC (79). In addition, red pulp macrophages, expressing CD11cint and F4/80hi, acquired antigen via the mannose receptor to cross-present AdLGO adenovirus-expressing ovalbumin which led to control of early viral infection [120] (Table 1). In this study, SpiC−/− mice (SpiC is required for the development of red pulp macrophages) had a higher viral burden at an earlier timepoint compared to Batf3−/− mice (which lack cross-presenting cDC1s) and viral clearance was achieved at 10 days [120]. These findings demonstrate that red pulp macrophages are important during early viral infection by presenting viral antigens to CD8+ effector T cells, while cDC1s help in later viral clearance. These studies demonstrate the importance of macrophages in both antigen exchange and antigen presentation which can shape the immune response.

Macrophages

Macrophages are derived from the same myeloid progenitors as DCs [112]. Macrophages express MHC class I and II, co-stimulatory molecules and can promote pro- or anti-inflammatory immune responses [113] (Table 1). Unlike DCs, macrophages are essential for removing apoptotic and necrotic cell debris at the site of inflammation. Of particular interest in antigen trafficking is the subcapsular sinus macrophage or CD169+ metallophilic macrophage (Table 1). These macrophages are strategically located near the subcapsular sinus of the LN or near the blood vasculature to capture incoming protein antigens and viruses (Fig. 1f, g). These CD169+ macrophages extend cellular processes to sample the afferent lymphatic fluids and blood for protein and viral antigens (Fig. 1f, g) [11, 114, 115]. The CD169+ macrophages can also capture large antigens, including vesicular stomatitis virus (VSV) antigens (Fig. 1f, g) [116]. These subcapsular macrophages have limited degradative properties, which allows them to hold antigens for up to three days [117]. The duration of antigen allows for migrating B cells to arrive at the subcapsular sinus, where macrophages present the antigen to cognate B cells and initiate the humoral response [11]. The duration of antigen requires the expression of CD169, a sulfated glycoprotein [117] (Table 1). Furthermore, CD169+ macrophages in the LN can capture and present lipid antigens to iNKT cells, which is critical in the activation and rapid secretion of IL-4 and IFNγ by iNKT cells [118]. The expression of CD14 on the CD169+ macrophages allows iNKT to come into close proximity with these macrophages for antigen presentation.

Monocytes can participate in antigen surveillance and acquire antigens prior to migrating to the LNs during steady state [121]. Monocytes in mice are Ly6C+MHCII+ and suggested to be the CD14+/CD16− subset in humans (Table 1) [122–124]. Immature monocytes, in addition to differentiated monocytes (monocyte-derived DCs or macrophages), can transport fluorescent ovalbumin at steady state or in an inflammatory state [124] (Fig. 1h). While Ly6C+MHCII+ monocyte populations are abundant at steady state, and increase dramatically during inflammation, other monocyte populations do differentiate into macrophages. Presentation of antigens by monocytes typically occurs via differentiation into monocyte-derived DCs [121]. The monocyte-derived DCs are thought to originate from monocytes, be similar to cDC2s in function, and expand during inflammation [121]. Thus, while monocytes participate in antigen trafficking...
many of their presentation capabilities require maturation into a type of inflammatory DC.

B cells

B cells are of particular importance as they encounter antigens within specific regions of the LN and spleen. There are three types of B cells, transitional B cells, marginal zone (MZ) B cells, and follicular B cells found in the lymphoid organs. Transitional B cells are those B cells that have come from the bone marrow and have yet to fully differentiate. As such they will not be described in detail within this section. An additional B cell subset, B1 B cells, can also be found within the lymphoid tissue but largely comprise the B cell populations of the pleural and peritoneal cavities [125]. These B1 cells can be delineated into B1a and B1b and can produce antibodies, primarily IgM, to different types of antigens (reviewed in [125]) and have a minor role in antigen trafficking. Each of these B cell types has unique features that contribute to antigen handling, recognition and antibody responses via class-switch recombination. Below we will further discuss the major B cell types involved in protein antigen handling and responses in the lymphoid organs.

Marginal zone (MZ) B cells

MZ B cells, along with DCs, macrophages, and granulocytes, are positioned within the marginal zone of the spleen where they readily encounter blood-borne pathogens. The marginal zone is located where large amounts of blood enter the MZ from the circulation (Fig. 1). Interestingly, MZ B cells in humans are freely circulating and can be found in other tissues besides the spleen. In humans, MZ B cells have high expression of CD1c (BDCA1) and CD19 while in mice, MZ B cells express B220, CD21 and CD1d (Table 1) [126, 127]. The MZ B cells in humans and mice express higher levels of IgM and lower levels of IgD (Table 1) [127, 128]. Blood-borne pathogens or small soluble antigens that enter the marginal zone are captured by CD169+ metallophilic macrophages or MZ macrophages and endocytosed via FcγRIIB, allowing the antigens to be held within non-degradative endosomal compartments [129]. Upon encounter with MZ B cells the CD169+ macrophages can recycle the intact antigens to the surface for recognition by the B cell receptor (Fig. 1i) [129, 130]. MZ B cells can quickly produce IgM antibodies in response to particulate bacterial antigens participating in very early defense against these pathogens [130]. Like other B cells, the MZ B cells can perform class-switch recombination to produce IgA or IgG, MZ B cells, however, require assistance from neutrophils and splenic sinusoidal endothelial cells [131]. MZ B cells are therefore critical in the initial recognition of antigens and at later times can be presented with antigens by CD169+ metallophilic and MZ macrophages to manipulate the immune response.

Follicular B cells

In the LN, small soluble antigens in the lymph diffuse in the subcapsular sinus into B cell follicles, where follicular B cells can encounter them (Fig. 1). These B cells express B220, CD19, MHC class II, CD23 in the mouse, and express CD19 and HLA-DR in human (Table 1) [126, 127]. Both also express high levels of IgD and low levels of IgM (Table 1) [127]. Analysis of antigen diffusion by electron microscopy or immunofluorescence suggests that antigens diffuse through pores or conduits in the subcapsular sinus to reach the follicular B cells and other areas of the LN cortex in mice (Fig. 1j) [17, 132]. Upon encounter with these antigens, follicular B cells internalize the B cell receptor bound soluble antigens and eventually (~24 h) display the antigenic peptide in the context of MHC class II for presentation to T cells which they encounter following CCR7 dependent T cell migration to the paracortex [133].

While small, soluble antigens can easily pass through the lymphatics and into the LN, larger antigens (e.g., VSV antigens) are captured by subcapsular sinus macrophages and DCs for recognition by follicular B cells. The subcapsular sinus macrophages act to sequester antigen near the sinus and B cell follicle where they can transfer unprocessed particulate antigens to follicular B cells (Fig. 1k) [11, 134]. The antigens are then internalized by follicular B cells which migrate to the edge of the follicle and interact with T cells and present the antigen [134].

During DC-mediated presentation to B cells, DCs endocytose antigens via FcγRIIB. Endocytosis via the FcγRIIB prevents degradation of the protein antigen via non-degradative endocytic compartments and promotes recycling of the antigen to the surface for recognition by the B cell receptor [129]. Indeed, a DC population in the paracortex presents intact and unprocessed antigens to B cells [135, 136]. DC populations concentrated in the paracortex around the HEV interact with migrating B cells as a mechanism for antigen recognition by the B cell and to promote T cell dependent antibody production (Fig. 11) [135]. Upon encounter, the B cells slow down and interact with the DC for activation of the B cells, which can give rise to extrafollicular plasma cells [135]. Like MZ B cells, follicular B cells are important for shaping the immune response and thus trafficking antigen to the follicular B cells is critical for optimal antigen presentation, antibody production, and coordination of immunity.
Neutrophils

Neutrophils (Lin−, CD45+, CD11bhi in mouse and human, Ly6C+ in mouse, MPO+, Elastase+ in human) [137–139] are the first responders to sites of inflammation and aid in the recruitment of other leukocytes through the release of mediators (Table 1). While many of the recruited neutrophils contract via cell death at the site of inflammation, emerging evidence has demonstrated that neutrophils have the capacity to traffic antigens to LNs (Fig. 1m) [140, 141]. In beautiful imaging studies, higher numbers of photoconvertible neutrophils were detected within the draining LNs only when Staphylococcus aureus was administered to the mouse ear compared to scarification without the bacteria [141]. These findings implicate neutrophil migration as an additional mechanism of antigen transport, at least during bacterial infection. Further evidence indicated neutrophils migrate to the LN via the lymphatic vasculature and can traffic fluorescent ovalbumin administered in Complete Freund’s Adjuvant [142]. Neutrophil migration was dependent on TNFα produced from tissues, as well as CD11b and CXCR4, but not CCR7 (though CCR7 was important at homeostasis) [140]. Thus, neutrophils are another mechanism of antigen transport from the site of infection or injury that is important for modulating the immune response.

Conclusions for protein transport

Antigen can traffic both passively and actively. Active antigen trafficking requires several different cell types and the movement of these cells from the tissue, through the blood, lymph and into the spleen and LNs. Passive antigen trafficking to the LN or spleen does not require cellular transport and instead results in antigen acquisition by LN or spleen resident cells (DCs, macrophages, B cells, etc.). The timing of these trafficking events occurs within the first week after activation (Fig. 1a). This is a coordinated process that is required for detection of the antigen and/or pathogen and for forming the immune response. As discussed above, the cell types that encounter the antigen shape the type of immune response and work together with other cell types to amplify the response and clear the infection.

Protein antigen retention

In addition to antigen trafficking several studies have also highlighted the importance of antigen retention after vaccination [3–5] or after infection [143–148]. This type of antigen retention (also called antigen persistence, residual antigen, or antigen archiving) has been described as antigen remaining within the lymphoid tissue in mice in the absence of infection and beyond the peak of the immune response (Fig. 2a). This antigen persistence is different from chronic antigen or antigen depots. Chronic antigen is defined as antigen that remains due to chronic infection and antigen depots. In chronic depots, antigen is maintained for long periods of time at an injection site [149] ultimately trapping cells in the site where they become tolerized or die. In the case of chronic infection, antigen is present as a result of unchecked viral replication which causes clonal exhaustion [150–152]. As stated above, antigen archiving, persistence, or residual antigen is described as antigen that remains beyond the primary immune response and that is beneficial to immunity.

Cell types involved in antigen retention

As discussed above there are various documented cases in which vaccine antigens or viral antigens remain in the host for beyond detection of virus in humans, or beyond the primary immune response in mice. In most cases there is no longer detectable virus at the late time points in which either antigen-specific responses are detected or viral or vaccine proteins are detected (Fig. 2a). These factors led to remaining questions about which cell types are involved in the retention of non-replicating virus or protein antigens. Interestingly, all detection of antigens post-infection or vaccination is within lymph node stromal cells (LNSC) which require minimal turnover. Below are the LNSCs that have been described to be capable of antigen retention.

Follicular dendritic cells

Follicular dendritic cells (FDCs) are a radio-resistant stromal fibroblast subset that can capture and harbor antigen over extended periods of time (Fig. 2b) [144, 153–156]. The mechanism by which FDCs hold antigen is largely through antigen/antibody complexes and their interaction with CR1 (CD35) and CR2 (CD21) (Table 1) [153, 157–161]. CR1 and CR2 are also expressed by human FDCs, along with CR3 [162, 163] (Table 1). FDCs can acquire very small antigens directly via the LN conduit system or larger antigens from B cells (Fig. 2b) [16, 164, 165]. More specifically, immune complexes (antigen, IgM or IgG, and C3d/C3b opsonins) are captured by subcapsular sinus macrophages before being transferred to follicular B cells. The FDCs are then thought to acquire the antigen from B cells as a result of high expression of CR2 which could potentially strip the follicular B cell of its antigen–antibody complex (Fig. 2b) [165]. It was shown in mice that the duration of antigen persistence of antigen–antibody complexes within FDCs is quite long and involves the recycling of the unprocessed antigen stored in endosomes to the FDC surface for presentation to B cells [153]. It is predicted that FDCs acquisition and storage of
Fig. 2  Retention of foreign antigen within the lymph node.  

a) Antigen retention occurs approximately 5–30+ days after the initial onset of vaccination [3–5] or infection [143–148] with a foreign antigen.  
b) Follicular dendritic cells retain HIV and protein antigens via immune complexes bound to the CR2 receptor (CD21) [148–151].  
c) Soluble vaccine and viral antigen are retained by lymphatic endothelial cells for up to 5 weeks post vaccination [3, 5].  The LECs exchange the antigen to migratory DCs for the antigen to be presented in the lymph node to memory T cells to promote effector memory function [4].  

Although the location within the lymph node is unknown, both influenza (nuclear protein) and VSV have suggestive evidence of long-term antigen retention within the lymph node [4, 202].  
d) Respiratory viral antigen within the lung draining lymph node has been shown to result in antigen-specific effector memory T cells for over one month after infection [147, 148, 198].  These effector memory T cells patrol the lumen of the respiratory tract and can protect against secondary infection from influenza [144, 197].  
e) CD34+ fibroblasts within the subcapsular sinus and Nr4a1+ fibroblasts within the medullary cord retain soluble vaccine antigen for up to 2 weeks [5].
antigen is a mechanism by which memory B cells can react to FDC held antigens to maintain memory B cell function. The purpose behind FDC antigen–antibody complex retention is in germinal center development, B cell activation, affinity maturation, and B cell memory.

**Lymphatic endothelial cells**

Lymphatic endothelial cells (LECs) line the lymphatic vasculature and are important for draining interstitial fluid, antigens, and immune cells from the periphery to the draining LN. They express VEGFR3, LYVE1, Prox1, and Podoplanin in mice and human [5, 166–173] (Table 1). Within the LN, LECs are comprised of subcapsular, cortical and medullary LECs [171] that are defined by specific markers that distinguish function as well as location [172, 173]. We described an additional role for LECs in the retention or archiving of viral and vaccine antigens for more than 5 weeks which was dependent on innate immune activation in mice (e.g., polyI:C and other TLR agonists) (Fig. 2c) [4]. Notably, antigens associated with vaccinia infection (VV-ova) but not *Listeria monocytogenes* infection (LM-ova) were archived [4]. Whether it is the type of innate immune activation that is required for LEC antigen archiving (e.g., viral versus bacterial) or the size of the pathogen (e.g., 20–100 nm versus 400–1000 nm) is still unclear.

LECs also have an important role in maintaining peripheral tolerance [2, 174–177]. However, in the case of antigen archiving, LECs exchange antigens with DCs to promote productive immune responses (Fig. 2c) [3]. Importantly, LEC antigen archiving was important for enhancing the CD8+ T cell response during a secondary challenge in the mouse [4]. Future studies are required to understand what defines whether an LEC archives or presents a foreign antigen [2, 178]. One potential clue is that antigen archiving is dependent upon addition of an innate stimulus [4]. While the process by which metallophilic macrophages, DCs, or FDCs endocytose and maintain unprocessed antigens involves FcγRIIB, it is unclear how LECs maintain unprocessed antigens. However, based on transcriptional data of antigen high LEC populations, we identified caveolin-mediated endocytosis as a potential candidate by which LECs endocytose antigens [5]. Future studies of LEC antigen archiving are required to fully understand if antigens are held within caveosomes and if they are recycled back to the surface.

Antigen that resides in the host for long periods of time within the LN, is important for immune memory, and resides within LECs of the LN, is termed antigen archiving. Antigen that is held within other cell types or undescribed cell types with less information about the impact of the antigen duration has been termed antigen persistence. The difference between archiving and persistence is largely semantic, however we will use the terminology interchangeably referring to the process as persistence or archiving as described by the authors in the publications reviewed.

**Other LN fibroblasts**

The uniquely described ability of FDCs to retain antigen–antibody complexes suggests that other fibroblasts [179] may be able to perform this type of function. However, there are limited data describing other fibroblastic reticular cells as a cell type that acquires or retains foreign antigens, in fact, the majority of the data suggest otherwise [3, 4]. However, in our recent report we discovered fibroblast subsets, based on their transcriptional signature, within the draining LN of mice [179], retained low but detectable levels of barcoded antigen within the Nr4a1+ and CD34+ fibroblasts for 2 weeks (Table 1 and Fig. 2e) [5]. Interestingly, these subsets are in close proximity to the lymphatics that drain the vaccine antigens and could be an alternative source by which LECs acquire antigens over time for transfer to DCs [3]. Thus, previously unrecognized participation of antigen retention by LN fibroblasts may also have an important part in manipulating the immune response, though how this may occur can only be speculated.

**Vaccines and infections that cause antigen retention**

As mentioned above, all antigen retention occurs within the lymph node stromal cell (LNSC) populations. As the studies on LNSCs and their capacity to acquire and hold antigens is limited, additional studies are required to fully understand this process during different types of infections/vaccinations. In the section below, we will highlight what is known about the types of vaccinations and infections that have been demonstrated or predicted to result in prolonged vaccine or viral antigen within the host LNSCs.

**Vaccination**

Vaccine antigens can remain in the host due to vaccine antigen depots or vaccine antigen persistence. Antigen depots arise from substances within vaccinations, such as alum, and release vaccine antigens over time as the depot is broken down. Antigen depots are minimally beneficial to the cellular immune response [149]. Vaccine antigen persistence arises due to small soluble antigens being acquired by stromal cells within the LN. Studies of vaccine antigen persistence in mouse models have detected small soluble protein antigens, including viral proteins, within the draining LNs for up to 5 weeks post vaccination (Fig. 2c) [3–5]. Similarly, intradermal injection of virus-like particles (VLP)
s, was detected for as long as 6 days within the four draining LNs as measured in vivo using an IR dye to image the mouse daily [7]. In this study it was not determined if the duration of the VLP was longer than 6 days or if 6 days was the limit of detection with the IR dye or by which cell type the antigen was held.

In another report, the length of antigen persistence was directly associated with the amount of antigen administered as well as the signals received [4]. As such, the induction of an active immune response acted to facilitate an increased duration of antigen within the LN [4]. This report demonstrated that the persistent antigen was held by LECs [4]. The process was termed antigen archiving. Antigen persistence/archiving was independent of the type of protein or the type of TLR agonist, though antigen size was a determinant and some TLR agonists were better than others [4]. As an example, conjugation of the antigen to a TLR agonist resulted in a robust CD8 antigen-specific response and increased antigen persistence/archiving by LECs in mice [5]. It is noteworthy that antigen-TLR conjugation increased the duration of DC antigen presentation [180] similar to other antigen-TLR conjugate vaccine platforms [181, 182] and potentially increased the duration of antigen within the DC and possibly LEC or fibroblasts [5]. Whether the DC retained the antigen or received the antigen from another cell type (e.g., LEC, FDC or other fibroblast) was not demonstrated. However, in another report we documented the process of LEC–DC antigen exchange which occurred with archived antigen [3]. These findings suggest that detection of antigen within DCs using this methodology may be due to antigen exchange rather than DC antigen retention. Thus, vaccination with a spectrum of vaccine adjuvants and antigens can initiate antigen archiving and benefit long-term protective immunity.

In addition to LEC antigen archiving following vaccination, other reports have demonstrated the long-term retention of antigen–antibody complexes by FDCs following immunization [153, 183]. In these studies, immune complexes were detected following immunization with phycoerythrin (PE) and were taken up by B cells which were handed off to FDCs [153]. The unprocessed injected antigen–antibody complexes were detected for up to 16 days after immunization and predicted to be much longer based on in silico modeling [153, 183]. These findings also demonstrated that antigen amount and antigen half-life (depending on the protein antigen administered) would affect the duration within the FDC [183]. Indeed, the recycling of antigen by the FDCs was important in both mouse and human for promoting memory B cell responses. However, new transcriptional data also suggest FDC-retained antigens may have a regulatory function via PD-L1–PD-1 interactions between FDCs and T cells [184].

Together these data demonstrate a significant role for LNSCs in regulating antigen persistence/archiving following vaccination. Whether current vaccines, such as mRNA-based vaccines, induce antigen retention by either LECs or FDCs is yet to be determined. Based on the premise of these types of vaccines, translation of mRNA into protein, it is possible that mRNA vaccine encoded proteins are retained by LNSCs. That said, the location of the vaccine encoded protein and whether LNSCs have access to the protein, would likely influence whether or not this is possible. Additionally, while the exact mechanisms of how antigens are retained are still not well understood there are several key pathways that could initially be targeted (e.g., Caveolin mediated endocytosis, CR2 or FcγRII) to promote antigen retention. As we begin to better understand how antigens become archived or persist, testing if those pathways will be valuable to target in new vaccines will be necessary.

HIV

HIV is a chronic infection that results in the depletion of CD4+ T cells, leading to acquired immunodeficiency syndrome (AIDS). The virus’s ability to integrate into the genome of host cells that survive infection can lead to re-infections. Latent infection in CD4+ memory T cells is the cause of most of the virus’ persistence phenotype [185]. Another form of long-term viral reservoir is in myeloid cell types [185]. Even following antiretroviral therapy, HIV antigens can be detected within viral reservoirs. These viral reservoirs are known to contribute to the continual relapse of HIV infection [186]. It has been suggested that infectious HIV is kept in FDC reservoirs via complement receptor 2 (CD21/CD35) binding to complement C3d [187] (Fig. 2b and Table 1). Heesters et al. demonstrated that FDCs isolated from HIV-infected individuals could transmit the virus when co-cultured with uninfected human CD4+ T cells [187]. Furthermore, when HIV+ FDCs were pre-treated with soluble CD21-Ig and then co-cultured with uninfected human CD4+ T cells there was a significant reduction in HIV RNA copy number compared to the isotype control [187]. These findings suggest that C3d binding to CD21 promotes the release of infectious HIV. Intriguingly, HIV antigens have been detected in FDCs for years after an infection [188, 189]. Most notably, the HIV antigen p24, a capsid protein, was detected in FDCs in mice for nine months after initial infection [190]. Additionally, macrophages and microglia can harbor p24 antigen in vitro making the cells that survive viral infection an additional viral reservoir [191]. However, it remains unclear whether these cells are harboring viral antigen from a primary infection, or if the infected cells are continuing to make new viral particles. Thus, while HIV is considered a chronic infection with viral reservoirs, the question still remains whether FDCs can retain viral antigens...
in antigen–antibody complexes or if the virus hijacks the ability of the FDC to retain antigen–antibody complexes within non-degradative FcγRII positive endosomal compartments to protect the HIV from degradation [153].

Vaccinia virus

Vaccinia is an enveloped virus belonging to the poxvirus family. Vaccinia virus is largely tropic to livestock and was initially discovered by Edward Jenner in milk maids [192]. Since this discovery, vaccination with vaccinia largely eradicated the smallpox virus. The use of this virus in laboratory animals to understand viral pathogenesis and host–pathogen interactions has increased our understanding of how viruses in general affect the host. Since vaccinia virus is small it can directly traffic to the lymphatics, particularly when the virus is administered subcutaneously in mice and is not given ample time to infect skin cells [4, 19]. Recent studies with mice have demonstrated that virus administered via scarification, which results in infection of the keratinocytes and DDCs, caused the lymphatic vasculature to “close” to impede viral dissemination to the draining LN [19]. While virus is unable to enter the lymphatics, clearance of the virus does require DC migration. The DCs required for trafficking and promoting clearance of the skin infection are langerin + DDCs which promote robust CD8+ T cell responses [96–98]. Vaccinia viral proteins, but not pathogenic virus, can also be retained within the skin-draining LN for at least five weeks post footpad injection (Fig. 2c) [3, 4, 193]. The cell type required for harboring the vaccinia viral antigens is the LECs [3, 4]. The archival of these viral antigens appears to be important for modulating T cell responses, similar to vaccination [4], rather than FDC retention of antigens which is important for B cell responses [3, 4, 153, 165]. Therefore, vaccinia viral infection is the only virus that has been demonstrated to result in LEC antigen archiving.

Respiratory viruses: influenza and sendai

Each year the influenza virus (flu) infects, on average, one in five people around the world and causes five-hundred thousand deaths [194]. Despite high vaccination rates the flu virus remains highly prevalent in the population due to high antigenic drift and results in a flu vaccine efficacy of lower than 50% in some years [195]. Even in populations with high vaccination rates, the amount of antigenic drift can increase due to evolutionary pressure [196]. Thus, developing new vaccination strategies that mimic the protective immune response to flu are increasingly important.

Several reports have now demonstrated that influenza antigen is retained in mice for weeks after the peak of the immune response and beyond the detection of replicating virus [143, 148]. Specifically, viral influenza antigen can be detected for as late as 30 days in draining mediastinal LNs in mice (Fig. 2d) [148]. The residual flu antigens found in the LNs are thought to periodically stimulate T cell proliferation and maintain an effector-like phenotype for the duration of antigen retention [144, 197] this is similar for other respiratory viruses such as Sendai virus [147, 198] (Fig. 2d). Thus, persistence of respiratory viral antigens promotes highly active viral antigen-specific T cells for a duration that is in line with seasonal respiratory infections. Perhaps, the increased number and effector phenotype of the flu specific CD8+ T cells may be important for minimizing re-infection during the flu season. Based on the duration of flu antigens within the lung draining LNs and the substantial benefit to protective immunity, it is tempting to speculate that flu antigens are also “archived” by LECs in a similar to vaccinia virus.

Vesicular stomatitis virus

Vesicular stomatitis virus (VSV) is a member of the Rhabdovirus family. VSV is transferred horizontally from insects to mammals [199] and host survival is linked to a strong type-I-interferon response [200]. VSV infection in humans is rare, but outbreaks in cattle can have significant economic impact estimated at a loss of $100–200 per infected cow [201]. As with both influenza and vaccinia viral infection, VSV antigen was measurable in mice more than 6 weeks after infection in draining LNs, well beyond detection of the infectious virus (Fig. 2c) [202]. The location of antigen retention within the LNs was not explored, however, based on our understanding of antigen persistence/archiving and the turnover of hematopoietic cells within the LN, it is likely the antigen is within a LNSC.

COVID-19

Some individuals infected with SARS-CoV-2 have long-term symptoms for as long as 110 days, dubbed as “long-haulers” [203]. It is unclear the cause of these long-hauler symptoms, however, one study has shown SARS-CoV-2 antigen in biopsies of human enterocytes from a patient 92 days after the onset of symptoms [204]. It is unclear if the virus is infecting and replicating within these cells or if the viral antigen is being retained to protect from future infections. Growing evidence suggests that in patients who no longer have detectable respiratory swab viral loads, these patients can have fecal samples with detectable viral loads for nearly five weeks after negative respiratory swabs [205]. This suggests that SARS-CoV-2 infection may become chronic in these individuals. However, whether SARS-CoV-2 antigens, like other viral antigens [144–146, 148, 206], persists or is archived as a mechanism to stimulate either B or T cells
for longer periods of time is unknown. It seems most likely that symptoms in “long-haulers” is due to chronic infection rather than persistence or archiving. However, it is possible that a reservoir of SARS-CoV-2 persists within a LNSC using a mechanism of persistence similar to HIV.

Conclusions

Here we have outlined cell types, tissues, and types of protein antigens and infections required for antigen dispersal, persistence and archiving. While numerous factors are responsible for where protein antigens traffic, which cell types are important for protection against pathogens and the antigens they release, and how antigens are retained for future stimulation, we still have much to understand. Of particular interest is how the location of the protein antigen can determine the type of cell-mediated response required, i.e., the type of antibody response, the type of Th response, and cytotoxic response. Indeed, these responses are much more well described than antigen persistence or archiving, but there are still gaps in our understanding due to lack of visibility of antigens upon entry into the host. As single cell technology and high-resolution imaging improves our detection of antigens, it will be important to utilize the technology to enhance our understanding of antigen trafficking. There is still much to learn about the retention, persistence, and archiving of protein antigen. Key areas of investigation should include which viruses and/or other pathogens can initiate antigen archiving. We highlighted several types of infections here and only one has been demonstrated to initiate LEC antigen archiving (Vaccinia Virus). Interestingly, LECs have also been shown to take up Chikungunya viral RNA, however, the duration of the virus within LECs is unknown [207]. Others, like flu and VSV, that have similar effects on memory T cell responses are potential candidates for viruses that induce LEC antigen archiving. Additionally, based on the positive impact of LEC antigen archiving on memory responses and the possibility of achieving antigen archiving through vaccination, future vaccine platforms should attempt to leverage this process. Finally, as very little has been described regarding how viral or protein antigens are acquired by non-hematopoietic cells or how they are released or exchanged, future studies should focus on these mechanisms. Manipulation of the processes required for antigen archiving may ultimately lead to improved vaccines that provide robust memory to novel pathogens that we encounter. As mentioned above, determining if known mechanisms of antigen acquisition, such as caveolin-mediated endocytosis or FcγRII/CR2, can be targeted to enhance different cell types involved and the processes required for antigen retention will be important for improving vaccines. Furthermore, determining the best route of vaccination (intradermal, subcutaneous, intramuscular, intranasal, oral, systemic, etc.) for inducing antigen retention will be required to optimize the long-term protective capabilities of different vaccines.

Thus far, antigen retention by lymph node stromal cells (LNSC) following vaccination or infection has only been shown to benefit protective immunity. Whether there are circumstances in which vaccine or viral antigens, in the presence of an adjuvant, are retained by LNSCs to result in immune tolerance has yet to be described. However, many studies have demonstrated that LNSCs are major contributors to maintaining peripheral tolerance through their expression of peripheral tissue antigens in mice and humans [174, 175, 208–212]. Further, LECs that acquire whole ovalbumin protein after injection participate in T cell tolerance in the absence of an adjuvant in mice [2] in a similar manner to how LECs present peripheral tissue antigens (via expression of PD-L1) [175]. Whether this antigen acquisition and retention by LNSCs could be a protective mechanism in which LNSCs retain antigens to mute allergic responses in the absence of inflammation is unknown. Similar to DCs, LNSCs seem to require an activation signal (infection, adjuvant, inflammation), to proceed down the path of antigen retention rather than antigen presentation and immune tolerance. Only when a vaccine adjuvant was added to ovalbumin did LECs archive the ovalbumin for longer than 1 week [4] which was later exchanged at 2 weeks post-vaccine with a professional APC rather than being presented by the LEC [12]. The possibility still remains that viruses, as with HIV, can co-opt the process in which LNSCs retain antigens to maintain latent infection [187]. Indeed, a recent study demonstrated that Chikungunya virus is acquired by MARCO + LECs [207]. Whether these LECs act as a reservoir for the virus or are participating in immunity against the virus is still unknown. Much work still needs to be done to understand the mechanisms of antigen retention by LNSCs and the implications for immunity, allergy, and viral evasion.

Author contributions TD, TF and BT all contributed to the writing and conception of the review.

Funding BAT was funded by NIH R01 AI121209, R01 AI155474 and R21 AI155929, a Department of Medicine Outstanding Early Career Scholar and RNA Biosciences Initiative Clinical Scholar Award, the University of Colorado Anschutz Medical Campus GI and Liver Innate Immune Programs and the Waterman Family Foundation for Liver Research.

Availability of data and material All data and material within this review will be available.
Declarations

Conflict of interest We declare no competing interest.

Ethics approval and consent to participate This article complies with the current ethical laws of the United States.

Consent for publication T.D., T.F. and B.A.J.T consent for publication of this review.

References

1. Gerner MY et al (2017) Dendritic cell and antigen dispersal landscapes regulate T cell immunity. J Exp Med 214(10):3105–3122. https://doi.org/10.1084/jem.20170335
2. Hirose S et al (2014) Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells. J Immunol 192(11):5002–5011. https://doi.org/10.4049/jimmunol.1302492
3. Kedl RM et al (2017) Migratory dendritic cells acquire and present lymphatic endothelial cell-archived antigens during lymph node contraction. Nat Commun 8(1):2034. https://doi.org/10.1038/s41467-017-02247-z
4. Tamburini BA, Burchill MA, Kedl RM (2014) Antigen capture and archiving by lymphatic endothelial cells following vaccination or viral infection. Nat Commun 5:3989. https://doi.org/10.1038/ncomms4989
5. Walsh SM et al (2021) Molecular tracking devices quantify antigen distribution and archiving in the murine lymph node. Elife. https://doi.org/10.7554/eLife.62781
6. Manolova V et al (2008) Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 38(5):1404–1413. https://doi.org/10.1002/eji.200737984
7. Cubas R et al (2009) Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother 32(2):118–128. https://doi.org/10.1097/CJI.0b013e318181f3c4
8. Hickman HD et al (2011) Chemokines control naïve CD8+ T cell selection of optimal lymph node antigen presenting cells. J Exp Med 208(12):2511–2524. https://doi.org/10.1084/jem.20102545
9. Hickman HD et al (2008) Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes. Nat Immunol 9(2):155–165. https://doi.org/10.1038/nii1557
10. Norbury CC et al (2002) Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat Immunol 3(3):265–271. https://doi.org/10.1038/ni.762
11. Jun T et al (2007) Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 450(7166):110–114. https://doi.org/10.1038/nature06287
12. Kedl RM, Tamburini BA (2015) Antigen archiving by lymph node stroma: a novel function for the lymphatic endothelium. Eur J Immunol 45(10):2721–2729. https://doi.org/10.1002/eji.201545739
13. Perez-Shibayama C, Gil-Cruz C, Ludewig B (2019) Fibroblastic reticular cells at the nexus of innate and adaptive immune responses. Immunol Rev 289(1):31–41. https://doi.org/10.1111/imr.12748
14. Bajenoff M et al (2006) Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 25(6):989–1001. https://doi.org/10.1016/j.immuni.2006.10.011
15. Roozendaal R, Mebius RE, Kraal G (2008) The conduit system of the lymph node. Int Immunol 20(12):1483–1487. https://doi.org/10.1093/intimm/dxn110
16. Roozendaal R et al (2009) Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity 30(2):264–276. https://doi.org/10.1016/j.immuni.2008.12.014
17. Sixt M et al (2005) The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22(1):19–29. https://doi.org/10.1016/j.immuni.2004.11.013
18. Lucas ED et al (2020) PD-L1 reverse signalling in dermal dendritic cells promotes dendritic cell migration required for skin immunity. Cell Rep 33(2):108258. https://doi.org/10.1016/j.celrep.2020.108258
19. Loo CP et al (2017) Lymphatic vessels balance viral dissemination and immune activation following cutaneous viral infection. Cell Rep 20(13):3176–3187. https://doi.org/10.1016/j.celrep.2017.09.006
20. Moussion C, Girard JP (2011) Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature 479(7374):542–546. https://doi.org/10.1038/nature10540
21. Chen Q et al (2006) Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signalling mechanism. Nat Immunol 7(12):1299–1308. https://doi.org/10.1038/ni1406
22. Marchesi VT (1961) The site of leucocyte emigration during inflammation. J Exp Physiol Cogn Med Sci 46:115–118. https://doi.org/10.1113/exphysiol.1961.sp001522
23. Yoneyama H et al (2004) Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol 16(7):915–928. https://doi.org/10.1093/immunox/dx093
24. Lewis SM, Williams A, Eisenbarth SC (2019) Structure and function of the immune system in the spleen. Sci Immunol. https://doi.org/10.1126/sciimmunol.aau6085
25. Brandtzæg P et al (2008) Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol 1(1):31–37. https://doi.org/10.1038/mi.2007.9
26. Amerongen HM et al (1991) Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. J Acquir Immune Defic Syndr 4(8):760–765
27. Foster N et al (1998) Ulex europaeus 1 lectin targets microspheres to mouse Peyers’ patch M-cells in vivo. Vaccine 16(5):536–541. https://doi.org/10.1016/S0264-410X(97)00222-3
28. Gicheva N et al (2016) Siglec-F is a novel intestinal M cell marker. Biochem Biophys Res Commun 479(1):1–4. https://doi.org/10.1016/j.bbrc.2016.08.055
29. Verbrugghe P et al (2008) Clusterin in human gut-associated lymphoid tissue, tonsils, and adenoids: localization to M cells and follicular dendritic cells. Histochem Cell Biol 129(3):311–320. https://doi.org/10.1007/s00418-007-0369-4
30. Verbrugghe P et al (2006) Murine M cells express annexin V and follicular dendritic cells. Histochem Cell Biol 129(3):311–320. https://doi.org/10.1007/s00418-007-0369-4
31. Kim DY et al (2011) The airway antigen sampling system: respiratory M cells as an alternative gateway for inhaled antigens. J Immunol 186(7):4253–4262. https://doi.org/10.4049/jimmunol.1961.sp001522
32. Zgair A et al (2016) Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am J Transl Res 8(8):3448–3459
33. Zhang F et al (2018) Lacteal junction zipper protects against diet-induced obesity. Science 361(6402):599–603. https://doi.org/10.1126/science.aap9331
34. Chirdo FG et al (2005) Immunomodulatory dendritic cells in intestinal lamina propria. Eur J Immunol 35(6):1831–1840. https://doi.org/10.1002/eji.200425882
35. Goubier A et al (2008) Plasmacytoid dendritic cells mediate oral tolerance. Immunity 29(3):464–475. https://doi.org/10.1016/j.immuni.2008.06.017
36. Liu X et al (2021) Development of hedgehog pathway inhibitors Trafficking and retention of protein antigens across systems and immune cell types 1 3
37. Bernier-Latmani J, Petrova TV (2017) Intestinal lymphatic vasculature: structure, mechanisms and functions. Nat Rev Gastroenterol Hepatol 14(9):510–526. https://doi.org/10.1038/nrgastro.2017.79
38. Rehal S, von der Weid PY (2017) TNF-ΔARE mice display dysfunction in the frontiers. Nat Rev Immunol. https://doi.org/10.1038/nri.2017.12
39. SuI SH et al (2019) Gut microbiota regulates lactic acid production by inducing VEGF-C in intestinal villus macrophages. EMBO Rep. https://doi.org/10.15252/embr.201846927
40. Miquel-Clopes A et al (2019) Mucosal vaccines and technology. Clin Exp Immunol 196(2):205–214. https://doi.org/10.1111/cei.13285
41. Azizi A et al (2010) Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog 6(11):e1001147. https://doi.org/10.1371/journal.ppat.1001147
42. Chabot S et al (2006) TLRs regulate the gatekeeping function of the intestinal follicle-associated epithelium. J Immunol 176(7):4275–4283. https://doi.org/10.4049/jimmunol.176.7.4275
43. Nochi T et al (2007) A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med 204(12):2789–2796. https://doi.org/10.1084/jem.20070607
44. Kim SH et al (2011) M cells expressing the complement C5a receptor are efficient targets for mucosal vaccine delivery. Eur J Immunol 41(11):3219–3229. https://doi.org/10.1002/eji.201141592
45. Kim SH et al (2010) The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. J Immunol 185(10):5787–5795. https://doi.org/10.4049/jimmunol.0903184
46. Lavelle EC, Ward RW (2021) Mucosal vaccines—fortify the mesentery. Am J Pathol 187(4):798–807. https://doi.org/10.1084/jem.20070607
47. Iliff JJ et al (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 4(147):147ra111. https://doi.org/10.1126/scitranslmed.3003748
48. Johnston M et al (2004) Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res 1(1):2. https://doi.org/10.1186/1743-8454-1-2
49. Aspelund A et al (2015) A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 212(7):991–999. https://doi.org/10.4049/jem.20142290
50. Louveau A et al (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523(7560):337–341. https://doi.org/10.1038/nature14432
51. Louveau A et al (2018) CNS lymphatic drainage and neuro-inflammation are regulated by meningeal lymphatic vasa vasorum. Nat Neurosci 21(10):1380–1391. https://doi.org/10.1038/s41593-018-0227-9
52. Lundgaard I et al (2017) Lymphatic clearance controls state-dependent changes in brain lactate concentration. J Cereb Blood Flow Metab 37(6):2112–2124. https://doi.org/10.1177/027173 78X16661202
53. Roh JH et al (2012) Disruption of the sleep-wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer’s disease pathology. Sci Transl Med. 4(150):150ra122. https://doi.org/10.1126/scitranslmed.3004291
54. Da Mesquita S et al (2018) Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease. Nature 560(7717):185–191. https://doi.org/10.1038/s41586-018-0368-8
55. Durai V, Murphy KM (2016) Functions of murine dendritic cells. Immunity 45(4):719–736. https://doi.org/10.1016/j.immuni.2016.01.010
56. Poulin LF et al (2010) Characterization of human DNGR-1+ BDCA+ dendritic cells. J Exp Med 207(6):1261–1271. https://doi.org/10.1084/jem.20092618
57. Kumamoto Y et al (2013) CD301b(+)-dermal dendritic cells drive T helper 2 cell-mediated immunity. Immunity 39(4):733–743. https://doi.org/10.1016/j.immuni.2013.08.029
58. Tamura T et al (2005) IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J Immunol 174(5):2573–2581. https://doi.org/10.4049/jimmunol.174.5.2573
59. Brown CC et al (2019) Transcriptional basis of mouse and human dendritic cell heterogeneity. Cell 179(4):846-863.e24. https://doi.org/10.1016/j.cell.2019.09.035
60. Cisse B et al (2008) Transcription factor E2–2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell 135(1):37–48. https://doi.org/10.1016/j.cell.2008.09.016
61. Reizis B (2019) Plasmacytoid dendritic cells: development, regulation, and function. Immunity 50(1):37–50. https://doi.org/10.1016/j.immuni.2018.12.027
62. Schlecht G et al (2004) Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming. J Immunol 173(10):6089–6097. https://doi.org/10.4049/jimmunol.173.10.6089
63. Desch AN et al (2014) Dendritic cell subsets require c-act-ivation for cytotoxic CD8 T cell induction. Nat Commun 5:4674. https://doi.org/10.1038/ncomms5674
64. Nizza ST, Campbell JJ (2014) CD11b+ migratory dendritic cells mediate CD8 T cell cross-priming and cutaneous imprinting after topical immunization. PLoS ONE 9(3):e91054. https://doi.org/10.1371/journal.pone.0091054
65. Cao X et al (2002) CD1 molecules efficiently present antigen in immature dendritic cells and traffic independently of MHC class II during dendritic cell maturation. J Immunol 169(9):4770–4777. https://doi.org/10.4049/jimmunol.169.9.4770
66. van der Wel NN et al (2003) CD1 and major histocompatibility complex II molecules follow a different course during dendritic cell maturation. Mol Biol Cell 14(8):3378–3388. https://doi.org/10.1091/mbc.e02-11-0744
67. Gras S et al (2016) T cell receptor recognition of CD1b presenting a mycobacterial glycolipid. Nat Commun 7:13257. https://doi.org/10.1038/ncomms13257
68. Melian A et al (2000) Molecular recognition of human CD1b antigen complexes: evidence for a common pattern of interaction with alpha beta TCRs. J Immunol 165(8):4494–4504. https://doi.org/10.4049/jimmunol.165.8.4494
69. Reineveld JF et al (2020) Human gammadelta T cells recognize CD1b by two distinct mechanisms. Proc Natl Acad Sci U S A 117(37):22944–22952. https://doi.org/10.1073/pnas.2010545117
70. Forster R et al (1999) CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99(1):23–33
71. Jackson DG (2019) Leucocyte trafficking via the lymphatic vasculature—mechanisms and consequences. Front Immunol 10:471. https://doi.org/10.3389/fimmu.2019.00471

72. Rouzaut A et al (2010) Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-alpha. Eur J Immunol 40(11):3054–3063. https://doi.org/10.1002/eji.201040523

73. Gerner MY, Torabi-Parizi P, Germain RN (2015) Strategically localized dendritic cells promote rapid T cell responses to lymphoborne particulate antigens. Immunity 42(1):172–185. https://doi.org/10.1016/j.immuni.2014.12.024

74. Bajenoff M, Glaichenhaus N, Germain RN (2008) Fibroblast-like reticular cells guide T lymphocyte entry into and migration within the splenic T cell zone. J Immunol 181(6):3947–3954. https://doi.org/10.4049/jimmunol.181.6.3947

75. Calabro S et al (2016) Differential intrasplenic migration of dendritic cell subsets tailors adaptive immunity. Cell Rep 16(9):2472–2485. https://doi.org/10.1016/j.celrep.2016.07.076

76. Edelson BT et al (2010) Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. J Exp Med 207(4):823–836. https://doi.org/10.1084/jem.20091627

77. Siegal FP et al (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284(5421):1835–1837. https://doi.org/10.1126/science.284.5421.1835

78. Hadeiba H et al (2012) Plasmacytoid dendritic cells transport peripheral antigens to the thymus to promote central tolerance. Immunity 36(3):438–450. https://doi.org/10.1016/j.immuni.2012.01.017

79. Young LJ et al (2008) Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nat Immunol 9(11):1244–1252. https://doi.org/10.1038/ni.1665

80. de Heer HJ et al (2010) Essential role of lung plasmacytoid dendritic cell subsets in regulating T cell responses. Front Immunol 1(1):260–270. https://doi.org/10.3389/fimmu.2019.00471

81. Sapoznikov A et al (2007) Organ-dependent in vivo priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells. J Exp Med 204(8):1923–1933. https://doi.org/10.1084/jem.20071966

82. Kissenpfennig A et al (2005) Dynamics and function of Langerin+ dermal dendritic cells. J Exp Med 204(13):3147–3156. https://doi.org/10.1084/jem.200504004

83. Tang A et al (1993) Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin. Nature 361(6407):82–85. https://doi.org/10.1038/361082a0

84. Gaiser MR et al (2012) Cancer-associated epithelial cell adhesion molecule (EpCAM; CD326) enables epidermal Langerhans cell motility and migration in vivo. Proc Natl Acad Sci U S A 109(15):E889–E897. https://doi.org/10.1073/pnas.1117674109

85. Villablanca EJ, Mora JR (2008) A two-step model for Langerhans cell migration to skin-draining LN. Eur J Immunol 38(11):2957–2980. https://doi.org/10.1002/eji.200838919

86. Hadeiba H et al (2012) Plasmacytoid dendritic cells transport of IgG into luminal secretions for delivery of antigens. Proc Natl Acad Sci U S A 109(15):E889–E897. https://doi.org/10.1073/pnas.1117674109

87. Tamburini AJ et al (2021) Contributions of PD-L1 reverse signaling to dendritic cell trafficking. FEBS J. https://doi.org/10.1111/febs.16084

88. Scandella E et al (2004) CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 103(5):1595–1601. https://doi.org/10.1182/blood-2003-05-1643

89. Yen JH, Khayruillina T, Ganea D (2008) PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 111(1):260–270. https://doi.org/10.1182/blood-2007-05-090613

90. Seneschal J, Jiang X, Kupper TS (2014) Langerin+ dermal DC, but not Langerhans cells, are required for effective CD8-mediated immune responses after skin scarification with vaccinia virus. J Invest Dermatol 134(3):686–694. https://doi.org/10.1038/jid.2013.418

91. Jiang X et al (2012) Skin infection generates non-migratory memory CDS+ T(RM) cells providing global skin immunity. Nature 483(7388):227–231. https://doi.org/10.1038/nature10851

92. Liu L et al (2010) Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 16(2):224–227. https://doi.org/10.1038/nm.2078

93. Harpur CM et al (2019) Classical type 1 dendritic cells dominate priming of Th1 responses to herpes simplex virus type 1 skin infection. J Immunol 202(3):653–663. https://doi.org/10.4049/jimmunol.1800218

94. Jakubzick C et al (2008) Blood monocyte subsets differentially give rise to CD103+ and CD103– pulmonary dendritic cell populations. J Immunol 180(5):3019–3027. https://doi.org/10.4049/jimmunol.180.5.3019

95. Desch AN et al (2011) CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J Exp Med 208(9):1789–1797. https://doi.org/10.1084/jem.20110538

96. Liu H et al (2017) Dendritic cell trafficking and function in rare lung diseases. Am J Respir Cell Mol Biol 57(4):393–402. https://doi.org/10.1165/rcmb.2017-0051PS

97. Veenenbergen S et al (2016) Colonic tolerance develops in the ileal lymph nodes and can be established independent of CD103 (+) dendritic cells. Mucosal Immunol 9(4):894–906. https://doi.org/10.1038/mi.2015.118

98. Kelsall BL, Strober W (1996) Distinct populations of dendritic cells in lymph nodes and can be established independent of CD103 (+) dendritic cells. Mucosal Immunol 9(4):894–906. https://doi.org/10.1038/mi.2015.118

99. Kelsall BL, Strober W (1996) Distinct populations of dendritic cells in lymph nodes and can be established independent of CD103 (+) dendritic cells. Mucosal Immunol 9(4):894–906. https://doi.org/10.1038/mi.2015.118

100. Jakubzick C et al (2008) Blood monocyte subsets differentially give rise to CD103+ and CD103– pulmonary dendritic cell populations. J Immunol 180(5):3019–3027. https://doi.org/10.4049/jimmunol.180.5.3019
to mucosal dendritic cells. Immunity 20(6):769–783. https://doi.org/10.1016/j.immuni.2004.05.007

108. Bain CC et al (2017) TGFbetaR signalling controls CD103(+) CD11b(+) dendritic cell development in the intestine. Nat Commun 8(1):620. https://doi.org/10.1038/s41467-017-00658-6

109. Kneebrew MA et al (2012) Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity 36(2):276–287. https://doi.org/10.1016/j.immuni.2011.12.011

110. Persson EK et al (2013) IRF4 transcription-factor-dependent CD103(+)CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation. Immunity 38(5):958–969. https://doi.org/10.1016/j.immuni.2013.03.009

111. Cerovic V et al (2015) Lymph-borne CD8alpha+ dendritic cells are uniquely able to cross-prime CD8+ T cells with antigen acquired from intestinal epithelial cells. Mucosal Immunol 8(1):38–48. https://doi.org/10.1038/mi.2014.40

112. Liu K, Nussenzweig MC (2010) Origin and development of Trafficking and retention of protein antigens across systems and immune cell types. Immunity 8(1):620. https://doi.org/10.1016/j.immuni.2010.06.007

113. Szakal AK, Holmes KL, Tew JG (1983) Transport of immune cells is uniquely able to cross-prime CD8+ T cells with antigen acquired from intestinal epithelial cells. Mucosal Immunol 8(1):38–48. https://doi.org/10.1038/mi.2014.40

114. Kastenmuller W et al (2012) A spatially-organized multicellular defense network connects germinal center and the follicle germinal center. PLoS Pathog 8(1):e1002354. https://doi.org/10.1371/journal.ppat.1002354

115. Enders M et al (2020) Splenic red pulp macrophages cross-prime CD11b(+) dendritic cell development in the intestine. Exp Immunol 127(2):220–225. https://doi.org/10.1046/j.1365-2249.2002.01774.x

116. Innaccone M et al (2010) Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature 465(7301):1079–1083. https://doi.org/10.1038/nature09118

117. Unanue ER, Cerottini JC, Bedford M (1969) Persistence of antigen on the surface of macrophages. Nature 222(5199):1193–1195. https://doi.org/10.1038/2222193a0

118. Barral P et al (2010) CD169+ macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 11(4):303–312. https://doi.org/10.1038/ni.1853

119. van Dinther D et al (2018) Functional CD169 on macrophages mediates interaction with dendritic cells for CD9(+) T cell cross-priming. Cell Rep 22(6):1484–1495. https://doi.org/10.1016/j.celrep.2018.01.021

120. Enders M et al (2020) Splenic red pulp macrophages cross-prime early effector CTL that provide rapid defense against viral infections. J Immunol 204(1):87–100. https://doi.org/10.4049/jimmunol.1900021

121. Jakubzick CV, Randolph GJ, Henson PM (2017) Monocyte and macrophage differentiation and antigen-presenting functions. Nat Rev Immunol 17(6):349–362. https://doi.org/10.1038/nri.2017.28

122. Randolph GJ, Jakubzick C, Qu C (2008) Antigen presentation by monocytes and monocyte-derived cells. Curr Opin Immunol 20(1):52–60. https://doi.org/10.1016/j.coi.2007.04.010

123. Yang J et al (2014) Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res 2(1):1. https://doi.org/10.1186/2050-7771-2-1

124. Jakubzick C et al (2013) Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 39(3):599–610. https://doi.org/10.1016/j.immuni.2013.08.007

125. Cunningham AF et al (2014) B1b cells recognize protective antigens after natural infection and vaccination. Front Immunol 5:535. https://doi.org/10.3389/fimmu.2014.00553

126. Kanayama N, Cascallo M, Ohmori H (2005) Analysis of marginal zone B cell development in the mouse with limited B cell diversity: role of the antigen receptor signals in the recruitment of B cells to the marginal zone. J Immunol 174(3):1438–1445. https://doi.org/10.4049/jimmunol.174.3.1438

127. Palm AE, Kleinau S (2021) Marginal zone B cells: from housekeeping function to autoimmunity? J Autoimmun 119:106207. https://doi.org/10.1016/j.jaut.2021.106207

128. Appelgren D et al (2018) Marginal-zone B cells are main producers of IgM in humans, and are reduced in patients with autoimmune vasculitis. Front Immunol 9:2242. https://doi.org/10.3389/fimmu.2018.02242

129. Bergtold A et al (2005) Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 23(5):503–514. https://doi.org/10.1016/j.immuni.2005.09.013

130. Martin F, Oliver AM, Kearney JF (2001) Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 14(5):617–629. https://doi.org/10.1016/s1074-7613(01)00129-7

131. Puga I et al (2011) B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol 13(2):170–180. https://doi.org/10.1038/ni.2194

132. Pape KA et al (2007) The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity 26(4):491–502. https://doi.org/10.1016/j.immuni.2007.02.011

133. Okada T et al (2005) Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 3(6):e150. https://doi.org/10.1371/journal.pbio.0030150

134. Carrasco YR, Batista FD (2007) B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 27(1):160–171. https://doi.org/10.1016/j.immuni.2007.06.007

135. Qi H et al (2006) Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science 312(5780):1672–1676. https://doi.org/10.1126/science.1125703

136. Wykes M et al (1998) Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T dependent response. J Immunol 161(3):1313–1319

137. Boettcher M et al (2020) Markers of neutrophil activation and extracellular traps formation are predictive of appendicitis in mice and humans: a pilot study. Sci Rep 10(1):18240. https://doi.org/10.1038/s41598-020-74370-9

138. Ho AS et al (2014) Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers. Oncotarget 5(2):473–480. https://doi.org/10.18632/oncotarget.1631

139. Rosales C (2018) Neutrophil: a cell with many roles in inflammation or several cell types? Front Physiol 9:113. https://doi.org/10.3389/fphys.2018.00113

140. Arakiasamy S et al (2017) Endogenous TNFalpha orchestrates the trafficking of neutrophils into and within lymphatic vessels during acute inflammation. Sci Rep 7:44189. https://doi.org/10.1038/srep44189

141. Hampton HR et al (2015) Microbe-dependent lymphatic migration of neutrophils modulates lymphocyte proliferation in lymph nodes. Nat Commun 6:7139. https://doi.org/10.1038/ncomms8139

142. Gorlino CV et al (2014) Neutrophils exhibit differential requirements for homing molecules in their lymphatic and blood trafficking into draining lymph nodes. J Immunol 193(4):1966–1974. https://doi.org/10.4049/jimmunol.1301791
143. Jelley-Gibbs DM et al (2005) Unexpected prolonged presentation of influenza antigens promotes CD4 T cell memory generation. J Exp Med 202(5):697–706. https://doi.org/10.1084/jem.20050227

144. Kim TS et al (2010) Antigen persistence and the control of local T cell memory by migratory dendritic cells after acute virus infection. J Exp Med 207(6):1161–1172. https://doi.org/10.1084/jem.20092017

145. Kim TS, Sun J, Braciale TJ (2011) T cell responses during influenza infection: getting and keeping control. Trends Immunol 32(5):225–231. https://doi.org/10.1016/j.it.2011.02.006

146. Takamura S et al (2010) The route of priming influences the ability of respiratory virus-specific memory CD8+ T cells to be activated by residual antigen. J Exp Med 207(6):1153–1160. https://doi.org/10.1084/jem.20090283

147. Woodland DL, Kohlmeier JE (2009) Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 9(3):153–161. https://doi.org/10.1038/nri2496

148. Zammit DJ et al (2006) Residual antigen presentation after influenza virus infection affects CD8 T cell activation and migration. Immunity 24(4):439–449. https://doi.org/10.1016/j.immuni.2006.01.015

149. McLachlan JB et al (2009) Dendritic cell antigen presentation drives simultaneous cytokine production by effector and regulatory T cells in inflamed skin. Immunity 30(2):277–288

150. Shin H et al (2009) A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 31(2):309–320

151. Wherry EJ et al (2007) Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27(4):670–684

152. Wherry EJ et al (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4(3):225–234

153. Heesters BA et al (2013) Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. Immunity 38(6):1164–1175. https://doi.org/10.1016/j.immuni.2013.02.023

154. McCloskey ML et al (2010) Acquisition and presentation of follicular dendritic cell-bound antigen by lymph node-resident dendritic cells. J Exp Med 208(1):135–148. https://doi.org/10.1084/jem.201000354

155. Skakal A.K., Tew JG (1992) Follicular dendritic cells: B cell proliferation and maturation. Cancer Res 52(19 Suppl):5554A–5556A

156. Tew JG, Phipps RP, Mandel TE (1980) The maintenance and regulation of the humoral immune response: persisting antigen and the role of follicular antigen-binding dendritic cells as accessory cells. Immuno Rev 53:175–201

157. Klaus GG et al (1980) The follicular dendritic cell: its role in antigen presentation in the generation of immunological memory. Immunol Rev 53:3–28

158. Qin D et al (1998) Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. J Immunol 161(9):4549–4554

159. Rozendaal R, Mebius RE (2011) Stromal cell-immune cell interactions. Annu Rev Immunol 29:23–43. https://doi.org/10.1146/annurev-immunol-031210-101357

160. Suzuki K et al (2009) Visualizing B cell capture of cognate antigen from follicular dendritic cells. J Exp Med 206(7):1485–1493. https://doi.org/10.1084/jem.20090209

161. Fang Y et al (1998) Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol 160(11):5273–5279

162. Reyes M et al (1985) Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 135(4):2687–2694

163. van Nierop K, de Groot C (2002) Human follicular dendritic cells: function, origin and development. Semin Immunol 14(4):251–257. https://doi.org/10.1016/s1044-5323(02)00057-x

164. Bajenoff M, Germain RN (2009) B cell follicle development remodels the conduit system and allows soluble antigen delivery to follicular dendritic cells. Blood 114(24):4989–4997. https://doi.org/10.1182/blood-2009-06-229567

165. Heesters BA, Myers RC, Carroll MC (2014) Follicular dendritic cells: dynamic antigen libraries. Nat Rev Immunol 14(7):495–504. https://doi.org/10.1038/nri3689

166. Burchill MA, Goldberg AR, Tamburini BAJ (2019) Emerging roles for lymphatics in chronic liver disease. Front Physiol 10:1579. https://doi.org/10.3389/fphys.2019.01579

167. Kong LL et al (2017) The optimum marker for the detection of lymphatic vessels. Mol Clin Oncol 7(4):515–520. https://doi.org/10.3892/mco.2017.1356

168. Lucas ED, Tamburini BAJ (2019) Lymph node lymphatic endothelial cell expansion and contraction and the programming of the immune response. Front Immunol 10:36. https://doi.org/10.3389/fimmu.2019.00036

169. Park SM et al (2014) Mapping the distinctive populations of lymphatic endothelial cells in different zones of human lymph nodes. PLoS ONE 9(4):e94781. https://doi.org/10.1371/journal.pone.0094781

170. Tamburini BAJ et al (2019) Chronic liver disease in humans causes expansion and differentiation of liver lymphatic endothelial cells. Front Immunol 10:1036. https://doi.org/10.3389/fimmu.2019.01036

171. Fujiwara N et al (2020) Single-cell mapping reveals new markers and functions of lymphatic endothelial cells in lymph nodes. PLoS Biol 18(4):e3000704. https://doi.org/10.1371/journal.pbio.3000704

172. Takeda A et al (2019) Single-cell survey of human lymphatics unveils marked endothelial cell heterogeneity and mechanisms of homing for neutrophils. Immunity 51(3):561–572.e5. https://doi.org/10.1016/j.immuni.2019.06.027

173. Xiang M et al (2020) A single-cell transcriptional roadmap of the mouse and human lymph node lymphatic vasculature. Front Cardiovasc Med 7:52. https://doi.org/10.3389/fcvcm.2020.00052

174. Nichols LA et al (2007) Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J Immunol 179(2):993–1003 (179/2/993 [pii])

175. Tewalt EF et al (2012) Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood 120(24):4772–4782. https://doi.org/10.1182/blood-2012-04-427013

176. Dubrot J et al (2014) Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4(+) T cell tolerance. J Exp Med 211(6):1153–1166. https://doi.org/10.1084/jem.20132000

177. Lund AW et al (2012) VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 1(3):191–199. https://doi.org/10.1016/j.celrep.2012.01.005

178. Vokali E et al (2020) Lymphatic endothelial cells prime naive CD8(+) T cells into memory cells under steady-state conditions. Nat Commun 11(1):538. https://doi.org/10.1038/s41467-019-14127-9

179. Rodda LB et al (2018) Single-cell RNA sequencing of lymph node stromal cells reveals niche-associated heterogeneity.
